Search Press releases Keywords From To 24 Sep 2024 UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 Read More 23 Sep 2024 UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis Read More 9 Sep 2024 New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease Read More 6 Sep 2024 Transparency notification BlackRock, Inc. Read More 6 Sep 2024 UCB presents new data across expansive epilepsies portfolio at 15th European Epilepsy Congress (EEC) Read More 5 Sep 2024 Transparency notification BlackRock, Inc. Read More Pagination First page Previous page Previous … Page 16 Page 17 Page 18 Page 19 Current page 20 Page 21 Page 22 Page 23 Page 24 … Page 20 of 65 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
